GlassScriptPhysician profile
Heidi A Essig
NPI 1265547137
$8,168.73
in general payments reported to CMS, 2019-2025
25 companies · $2,659 in 2025
The $2,659 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,055 · 2022: $1,062 · 2023: $1,419 · 2024: $1,973 · 2025: $2,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,658 · Education: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,658.03 |
| Education | $393.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,203.41 | 2021-2025 | Dupixent |
| Abbvie INC. | $822.83 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $618.50 | 2021-2025 | |
| Incyte Corporation | $607.54 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $600.65 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $522.24 | 2021-2024 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $492.71 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $401.20 | 2021-2025 | Tremfya |
| Pfizer INC. | $396.93 | 2021-2025 | |
| Amgen INC. | $345.36 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $330.56 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $316.05 | 2021-2025 | Taltz, Ebglyss |
| Organon LLC | $259.08 | 2025 | Vtama, Nexplanon |
| Genzyme Corporation | $257.32 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $213.13 | 2021-2024 | Siliq, Targretin, Duobrii |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $185.30 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $162.53 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $154.42 | 2024-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $90.42 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.53 | 2025 | Spevigo |
| Epi Health, LLC | $45.04 | 2022 | |
| Botanix Sb INC | $36.92 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $16.41 | 2024 | Nuzyra |
| Genentech USA, INC. | $16.14 | 2023 | Erivedge |
| Tactile Systems Technology INC | $14.51 | 2023 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Essig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.